Jardiance vs Lantus: Should You Combine Them, Switch, or Stay on One?

What Jardiance and Lantus Actually Do (and Why They Differ)

These two drugs lower blood sugar by mechanisms so different they barely overlap, which is exactly why they are often prescribed together. Jardiance blocks the SGLT2 transporter in the kidney, forcing roughly 60-90 grams of glucose out in the urine each day regardless of how much insulin you have circulating. Lantus, a synthetic long-acting insulin analogue, replaces or supplements the basal insulin your pancreas can no longer make reliably, acting over roughly 24 hours with no pronounced peak.

How Each Drug Handles Your Physiology Differently

The insulin-independent action of empagliflozin matters for women with significant insulin resistance, including those with PCOS or in perimenopause, because the drug keeps working even when your cells are ignoring insulin signals. Insulin glargine, by contrast, is entirely dependent on receptor binding and works less efficiently as insulin resistance climbs.

Empagliflozin also produces modest weight loss of 1.5-3 kg on average, mild blood pressure reduction of 3-5 mmHg systolic, and a 38% relative risk reduction in cardiovascular death in the EMPA-REG OUTCOME trial. Lantus, studied in the ORIGIN trial, did not reduce cardiovascular events compared to standard care over median 6.2 years of follow-up, though it provided excellent glycemic stability.

The Mechanism Gap That Makes Combination Logical

Because SGLT2 inhibition is glucose-dependent and insulin-independent, adding Jardiance to a Lantus regimen attacks blood sugar from two angles simultaneously. Lantus covers fasting glucose through overnight basal coverage. Empagliflozin trims glucose continuously through the kidneys throughout the day and night. The result in clinical practice is often better HbA1c reduction than either drug achieves alone, with an opportunity to lower the Lantus dose and thereby reduce hypoglycemia risk.

The Rationale for Combining Jardiance and Lantus

Combining an SGLT2 inhibitor with basal insulin is now recommended as a reasonable escalation strategy by the 2023 ADA Standards of Care, particularly in people with cardiovascular disease, heart failure, or chronic kidney disease, where empagliflozin's organ-protective effects add independent value beyond glucose control.

When Endocrinologists Reach for This Combination

Clinicians typically consider combining the two drugs in one of three patterns:

• You are on Lantus and your HbA1c is still above target despite titrated basal doses, but adding more insulin risks weight gain and hypoglycemia.
• You are on Jardiance and your fasting glucose remains elevated, signaling insufficient overnight insulin coverage.
• You have type 2 diabetes with established heart failure or stage 3 chronic kidney disease, where Jardiance adds specific benefit beyond glucose lowering.

The combination is not typically a first-line choice. Metformin remains the standard first agent for most women with type 2 diabetes. Basal insulin plus an SGLT2 inhibitor tends to come up after one or two oral agents have failed.

The Weight and Insulin-Dose Benefit Specific to Women

Women carry a higher proportion of body fat and experience more pronounced insulin resistance during hormonal shifts, including the luteal phase of the menstrual cycle, postpartum recovery, and perimenopause. Adding empagliflozin to basal insulin has been shown to reduce total daily insulin requirements by a meaningful margin. One pooled analysis of SGLT2 inhibitor add-on trials found insulin dose reductions of approximately 10 units per day alongside HbA1c improvements of 0.5-1.0%. Fewer units of insulin typically means less weight gain and less hypoglycemia, both of which matter more metabolically in women.

Risks of Combining Jardiance and Lantus: What Women Need to Know

The combination carries real risks that deserve direct conversation with your prescriber. The three that matter most for women are hypoglycemia, genital infections, and euglycemic diabetic ketoacidosis (euDKA).

Hypoglycemia: The Dose-Reduction Imperative

When empagliflozin is added to an existing Lantus regimen, blood sugar drops faster than either drug alone would suggest. The FDA label for empagliflozin states that the insulin dose should be reduced when initiating an SGLT2 inhibitor to reduce the risk of hypoglycemia. In practice, a 10-20% reduction in Lantus units at initiation is a common clinical approach, though exact titration depends on your baseline glucose and HbA1c.

Symptoms of hypoglycemia in women can be atypical, particularly in perimenopause, where hot flashes and night sweats mimic the sweating and palpitations of a low blood sugar event. If you are perimenopausal and on both drugs, keeping a continuous glucose monitor reading or a bedside glucometer is a practical safety measure.

Genital Yeast Infections and UTIs

Glycosuria, the glucose-in-urine that makes empagliflozin work, creates a sugar-rich environment in the vaginal and vulvar area. In the EMPA-REG OUTCOME trial, genital mycotic infections occurred in approximately 10% of women assigned to empagliflozin versus 1.5% of those on placebo. Lantus does not raise this risk at all.

Women who experience recurrent vulvovaginal candidiasis on Jardiance should tell their prescriber. This side effect does not always mean stopping the drug. Good hygiene, wearing breathable cotton underwear, and prompt treatment of infections are the first steps. Switching to a different SGLT2 inhibitor may help in persistent cases.

Euglycemic DKA: The Risk You Cannot See

Euglycemic DKA is a rare but potentially fatal condition where ketones accumulate to dangerous levels even though blood glucose reads near-normal, typically between 150-250 mg/dL. It occurs with SGLT2 inhibitors because the drug shifts energy metabolism toward fat oxidation and ketone production, and the effect is amplified when insulin doses are low or when you eat very little carbohydrate, fast for surgery, or are acutely ill.

The WomanRx clinical team recommends a practical rule for women on Jardiance plus Lantus: hold empagliflozin 72 hours before any planned surgery, prolonged fasting, or very low carbohydrate dieting. If you develop nausea, vomiting, abdominal pain, or feel unwell, check ketones immediately even if your glucose seems acceptable. This guidance aligns with FDA safety communication on SGLT2 inhibitors and DKA.

Life-Stage Guide: How This Combination Affects Women Differently

Reproductive Years and PCOS

Women with PCOS often have significant insulin resistance as a driver of their condition. Basal insulin is occasionally used in PCOS when metformin and lifestyle changes are insufficient, though it is not a first-line PCOS treatment. Empagliflozin is not FDA-approved specifically for PCOS, and evidence in that population remains limited. The data that exist are largely extrapolated from type 2 diabetes trials, which under-represented women with PCOS specifically. If you have PCOS and insulin resistance but not diagnosed type 2 diabetes, this combination is unlikely to be appropriate.

Perimenopause: The Window Where This Combination Becomes More Common

Estrogen decline during perimenopause increases visceral fat, worsens insulin sensitivity, and raises fasting glucose even in women who never had diabetes before. Women whose type 2 diabetes was previously well-controlled on a single agent may find their HbA1c climbing as they enter perimenopause. This is one of the most common clinical scenarios where adding Jardiance to Lantus or vice versa becomes relevant.

Menopausal hormone therapy does not eliminate this need but may modestly improve insulin sensitivity. The Menopause Society's 2023 position statement notes that systemic estrogen therapy can improve insulin sensitivity and reduce the risk of type 2 diabetes in eligible postmenopausal women. If you are perimenopausal and your diabetes is harder to manage, a conversation about concurrent hormone therapy is worth having.

Post-Menopause

After menopause, cardiovascular risk rises sharply. This is exactly where the proven CV benefit of empagliflozin becomes most directly relevant. In EMPA-REG OUTCOME, the 3-point MACE reduction of 14% relative risk versus placebo was driven substantially by a 38% relative reduction in cardiovascular death, a benefit that extends to post-menopausal women with established heart disease. Adding Jardiance to Lantus in a post-menopausal woman with type 2 diabetes and heart failure is one of the clearest supported uses of this combination.

Pregnancy, Lactation, and Contraception: Do Not Use Either Drug if You Are Pregnant

Both empagliflozin and insulin glargine carry specific pregnancy warnings, and they differ in an important way.

Empagliflozin (Jardiance): Contraindicated in the Second and Third Trimesters

The FDA pregnancy labeling for empagliflozin advises discontinuing the drug as soon as pregnancy is detected, given animal data showing fetal renal toxicity during the period of kidney development. Human data during the first trimester are insufficient to establish safety. The drug should not be used during pregnancy. Women of reproductive age who are sexually active and not using reliable contraception should discuss this explicitly with their prescriber before starting Jardiance.

Empagliflozin transfer into breast milk has been detected in animal studies. There are no adequate human lactation data. Because developing infant kidneys may be sensitive to SGLT2 blockade, the prescribing information advises against use during breastfeeding.

Insulin Glargine (Lantus): The Safer Option in Pregnancy, With Caveats

Lantus is not the preferred insulin in pregnancy. Human regular insulin and NPH insulin have the longest safety records in gestational and pre-existing diabetes. Insulin glargine has limited placental transfer and does not appear to cause fetal harm in available data, but ACOG and most obstetric guidelines still list NPH insulin as the preferred basal option during pregnancy due to the larger safety dataset. If you are pregnant and on Lantus, a switch to NPH under obstetric supervision is the standard recommendation.

During breastfeeding, insulin glargine is considered compatible. Very little crosses into breast milk, and oral absorption in the infant is negligible due to gastrointestinal protein digestion.

The practical bottom line: if you are on the Jardiance-plus-Lantus combination and you are planning pregnancy, stop Jardiance before attempting conception, transition to a pregnancy-appropriate insulin formulation with your OB and endocrinologist, and do not restart SGLT2 inhibitors until after weaning.

Should You Switch from Jardiance to Lantus, or from Lantus to Jardiance?

Switching rather than combining makes sense in specific clinical contexts. Here is how to think through it.

Switching from Jardiance to Lantus

This switch is appropriate when your beta cells have significantly declined and you can no longer produce enough endogenous insulin to benefit from glucose excretion alone. A declining C-peptide level, a rising fasting glucose that Jardiance alone cannot control, or a diagnosis that has evolved toward LADA (latent autoimmune diabetes in adults) all point toward adding or switching to basal insulin. Stopping Jardiance in this case removes the cardiovascular and renal benefits, so some clinicians will keep a low-dose SGLT2 inhibitor alongside insulin rather than stopping it entirely.

Switching from Lantus to Jardiance

This is less common and typically happens when insulin use is driving problematic weight gain, recurrent hypoglycemia, or significant quality-of-life burden and your residual beta-cell function is sufficient to maintain glucose control without exogenous insulin. C-peptide testing can confirm whether this is realistic. Stopping Lantus abruptly is never appropriate. Any transition away from basal insulin must be gradual, with close glucose monitoring.

Who This Combination Is Right For (and Who Should Avoid It)

Likely Candidates

• Women with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease stage 3-4
• Women whose HbA1c remains above 7.5% on optimized basal insulin despite dose titration
• Perimenopausal women with worsening glucose control and cardiovascular risk factors
• Women who need insulin for glycemic control but want to minimize insulin-related weight gain

Who Should Not Use This Combination

• Women who are pregnant or planning pregnancy in the near term
• Women with type 1 diabetes (euDKA risk is substantially higher)
• Women with estimated GFR below 30 mL/min/1.73 m2 (empagliflozin loses glycemic efficacy at this level, though it retains some renal protection; review with your nephrologist)
• Women with a history of recurrent DKA
• Women with recurrent, difficult-to-treat vulvovaginal candidiasis who cannot tolerate glycosuria

Evidence Gaps: What We Do Not Know Yet for Women

Women were included in EMPA-REG OUTCOME and ORIGIN but were not the majority of participants. In EMPA-REG OUTCOME, approximately 29% of participants were women, meaning subgroup analyses in women are underpowered to confirm sex-specific cardiovascular effect sizes. The cardiovascular benefit observed in the full trial is extrapolated to women rather than directly demonstrated in a female-powered subgroup.

No large trial has specifically examined the Jardiance-plus-Lantus combination in perimenopausal or post-menopausal women as a distinct population. Cycle-phase effects on SGLT2 inhibitor pharmacokinetics have not been formally characterized. Women with PCOS were excluded from the major SGLT2 inhibitor cardiovascular outcome trials. These are real gaps, not minor caveats.